ArticleAmerican journal of preventive cardiology2025
LDL-C targets based on coronary artery calcium: advancing Figure 6 from the 2022 American college of cardiology expert consensus decision pathway.
Article in American journal of preventive cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Is there a role for measuring coronary artery calcium progression in 2026?American journal of preventive cardiology · 2026Article
- The subclinical atherosclerosis clinic: Operationalizing opportunistic detection into cardiovascular preventive care.American journal of preventive cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The approach to LDL-C management in primary prevention has shifted from lipid-centric strategies to personalized, risk-based frameworks. However, the binary distinction between primary and secondary prevention may overlook individuals with advanced subclinical atherosclerosis. Coronary artery calcium (CAC) scoring has become central in identifying such patients, especially those whose risk exceeds that implied by traditional risk calculators. The 2022 ACC Expert Consensus Decision Pathway (ECDP) incorporated CAC into LDL-C goal-setting, advocating for LDL-C < 70 mg/dL when CAC >100 or >75th percentile. Emerging evidence suggests that CAC ≥300 portends risk comparable to clinical ASCVD, warranting even lower targets (<55 mg/dL). This editorial highlights how Figure 6 from the 2022 ECDP offers a framework for reclassifying high-risk individuals and recommends that future guidelines recognize CAC >300 as equivalent to secondary prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.